{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:39:26Z","timestamp":1767865166210,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009827","name":"Laura and John Arnold Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejca.2018.06.035","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T23:28:15Z","timestamp":1533684495000},"page":"244-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["A pooled analysis of published, basket trials in cancer medicine"],"prefix":"10.1016","volume":"101","author":[{"given":"Antonious","family":"Hazim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2018.06.035_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.5299","article-title":"Novel precision medicine trial designs: umbrellas and baskets","volume":"3","author":"West","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2018.06.035_bib2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2014.59.8433","article-title":"Basket trials and the evolution of clinical trial design in an era of genomic medicine","volume":"33","author":"Redig","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.035_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdw413","article-title":"Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples","volume":"28","author":"Renfro","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.035_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.2016.69.9751","article-title":"Basket trials in oncology: a trade-off between complexity and efficiency","volume":"35","author":"Cunanan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.06.035_bib5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ejca.2018.06.035_bib6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2018.06.035_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.06.035_bib8","series-title":"Adult soft tissue sarcoma treatment (PDQ\u00ae)\u2013Health professional version. Cancer types","year":"2018"},{"key":"10.1016\/j.ejca.2018.06.035_bib9","series-title":"Endometrial carcinoma: epidemiology and risk factors","year":"2017"},{"issue":"4","key":"10.1016\/j.ejca.2018.06.035_bib10","first-page":"156","article-title":"Analysis of histiocytosis deaths in the US and recommendations for incidence tracking","volume":"37","author":"Jain","year":"2010","journal-title":"J Regist Manag"},{"issue":"5","key":"10.1016\/j.ejca.2018.06.035_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jbspin.2009.01.014","article-title":"Langerhans cell histiocytosis revealed by painful hip: a case report","volume":"76","author":"Sabeur","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.035_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2334\/josnusd.58.67","article-title":"Incidence and survival rates for malignant salivary gland tumors","volume":"58","author":"Ata-Ali","year":"2016","journal-title":"J Oral Sci"},{"key":"10.1016\/j.ejca.2018.06.035_bib13","unstructured":"Quick Facts and Statistics for ACC. Adenoid cystic carcinoma organization international. Available at: http:\/\/www.accoi.org\/faq\/acc-statistics. [Accessed 24 July 2018]."},{"key":"10.1016\/j.ejca.2018.06.035_bib14","series-title":"Mesothelioma incidence and trends","year":"2018"},{"key":"10.1016\/j.ejca.2018.06.035_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of us patients with cancer who benefit from genome-driven oncology","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2018.06.035_bib16","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2012.46.8934","article-title":"Genomics-driven oncology: framework for an emerging paradigm","volume":"31","author":"Garraway","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.035_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41467-017-00451-5","article-title":"Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time","volume":"8","author":"Chia","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ejca.2018.06.035_bib18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/M15-2413","article-title":"GEnomic alteration\u2013driven clinical trial designs in oncology","volume":"165","author":"Simon","year":"2016","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ejca.2018.06.035_bib19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.molonc.2014.06.002","article-title":"The dream and reality of histology agnostic cancer clinical trials","volume":"8","author":"Lacombe","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2018.06.035_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2016.03.015","article-title":"Precision oncology: a new era of cancer clinical trials","volume":"387","author":"Renfro","year":"2017","journal-title":"Canc Lett"},{"issue":"2","key":"10.1016\/j.ejca.2018.06.035_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdx786","article-title":"Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of foundation medicine (F1CDx) before paying for it","volume":"29","author":"Prasad","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2018.06.035_bib22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat Rev Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T11:51:03Z","timestamp":1604749863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918309493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":22,"alternative-id":["S0959804918309493"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.035","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pooled analysis of published, basket trials in cancer medicine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}